The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.

Authors

Christos Mikropoulos

Christos Mikropoulos

Institute of Cancer Research, Sutton, United Kingdom

Christos Mikropoulos , Elena Castro , Elizabeth Bancroft , Elizabeth Page , Natalie Taylor , Tokhir Dadaev , Zsofia Kote-Jarai , Antonis C. Antoniou , Nandita DeSouza , Diana Keating , Edward Saunders , Doug Easton , Nigel Borley , Mahbubl Ahmed , Andrew Lee , Ros A. Eeles

Organizations

Institute of Cancer Research, Sutton, United Kingdom, The Institute of Cancer Research/Prostate Cancer Research Unit, London, United Kingdom, and Spanish National Cancer Research Centre,, Madrid, Spain, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom, University of Cambridge, Cambridge, United Kingdom, The Royal Marsden NHS Foundation Trust, London, United Kingdom, Center for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom

Research Funding

Other

Background: Prostate cancer (PC) screening is controversial and a better assessment of individualized PC risk is needed. Several single nucleotide polymorphisms (SNPs) conferring a cumulative risk of PC have been identified. We have explored the potential role of genetic markers for targeted screening in a population with increased risk of PC due to family history (FH). Methods: PROFILE was developed as a pilot study to determine the feasibility of targeted PC screening using prostatic biopsy (PB) and its association with specific genetic profiles in men with FH. We also evaluated the role of PSA and Diffusion Weighted MRI (DW-MRI) as screening tools. One hundred sixteen men age 40 to 69 with FH of PC were enrolled between October 2009 and December 2012. Cumulative SNP risk scores were calculated by summing 59 risk alleles for each locus using the weighted effect (log-additive model). DW-MRI was performed in 50 patients. Participants were asked to undergo a 10 core PB regardless of baseline PSA. Results: Median age 53 (40 to 69) and median PSA was 1.15. One hundred and two men accepted to undergo a PB as primary PC screening. Twenty-three tumours were found (22.5% of biopsies) as well as seven men diagnosed with atypical small acinar proliferation (ASAP) (6.8%) and eight men with high-grade prostatic intraepithelial neoplasia (HG-PIN) (7.8%). In total 37.1% received an abnormal result. Out of the diagnosed PC 41% were intermediate or high risk and requiring treatment, which compares with 24% in general population screening. The predictive performance of DW-MRI, PSA, genetic model and genetic model plus PSA measured by AUC were: 0.85, 0.73, 0.57 and 0.74, respectively. The genetic model performed best in men with a normal PSA of <3(AUC 0.63). Analyses of a 78 SNP profile from the recent COGS results are underway. Conclusions: Ourresults indicate that PB is acceptable for PC screening in men with FH of PC. The significant AUC for DW-MRI would warrant a larger study. The incidence of ASAP is higher in this group than the general population.The SNP risk score was more predictive in men with PSA less than three where PB would not normally be undertaken, therefore an expanded study to investigate the role of genetic profiling in directing PB in PC screening is indicated.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 22)

DOI

10.1200/jco.2014.32.4_suppl.22

Abstract #

22

Poster Bd #

B6

Abstract Disclosures

Similar Abstracts

Abstract

2013 ASCO Annual Meeting

Profile study: Genetic prostate cancer risk stratification for targeted screening.

First Author: Elena Castro

First Author: Alexandre Akoulitchev

First Author: Mahmood Moshiri